ViewPoint Therapeutics Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $61.4K
Latest Deal Amount
  • Investors
  • 14

ViewPoint Therapeutics General Information

Description

Developer of crystallin stabilizers designed to prevent and treat cataracts and presbyopia. The company's crystallin stabilizers include a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, enabling physicians to have drugs that prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases.

Contact Information

Website
www.viewpointtherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 290 Utah Avenue
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (628) 000-0000

ViewPoint Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ViewPoint Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 08-Nov-2019 $61.4K 0000 Completed Generating Revenue
5. Early Stage VC (Series B) 05-Mar-2018 0000 0000 0000 Completed Generating Revenue
4. Early Stage VC (Series A) 02-May-2016 00.000 00.000 000.00 Completed Generating Revenue
3. Grant 01-Apr-2016 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Accelerator/Incubator 06-Oct-2014 Completed Generating Revenue
To view ViewPoint Therapeutics’s complete valuation and funding history, request access »

ViewPoint Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view ViewPoint Therapeutics’s complete cap table history, request access »

ViewPoint Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of crystallin stabilizers designed to prevent and treat cataracts and presbyopia. The company's crystallin sta
Biotechnology
South San Francisco, CA
11 As of 2020
0000
0000000000 0 0000

00000000

ipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
0000000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

0000000

psum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolo
0000 000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ViewPoint Therapeutics Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Proclara Biosciences Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000 000000000000 Venture Capital-Backed Cambridge, United Kingdom 000.00 00000000000 000.00
000000000 00000000 Venture Capital-Backed Cambridge, MA 00 000.00 0000000000 0 000.00
000000000 Formerly VC-backed Copenhagen, Denmark 00 00000 000000000 00000
To view ViewPoint Therapeutics’s complete competitors history, request access »

ViewPoint Therapeutics Executive Team (10)

Name Title Board Seat Contact Info
Leah Makley Ph.D Co-Founder, President, Chief Executive Officer & Board Member
Noelynn Oliver Senior Director, Biology
Brian Connolly Senior Director Operations
Mike Lopez Ph.D Associate Director of Medicinal Chemistry
Bryan Dunyak Ph.D Associate Director of Research
You’re viewing 5 of 10 executive team members. Get the full list »

ViewPoint Therapeutics Board Members (7)

Name Representing Role Since
Edward Hurwitz Self Chairman 000 0000
Emmett Cunningham Ph.D ViewPoint Therapeutics Board Member 000 0000
Heath Lukatch Ph.D Self Board Member & Partner 000 0000
Leah Makley Ph.D ViewPoint Therapeutics Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Peter Moldt Ph.D Self Board Member & Partner 000 0000
You’re viewing 5 of 7 board members. Get the full list »

ViewPoint Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ViewPoint Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Novo Holdings Venture Capital Minority 000 0000 000000 0
The Rise Fund Impact Investing Minority 000 0000 000000 0
TPG Growth PE/Buyout Minority 000 0000 000000 0
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial